reports
- Jonathan Moreland
MTX MINERALS TECHNOLOGIES INC.
BUSE FIRST BUSEY CORPORATION
FLL FULL HOUSE RESORTS INC.
ALOT
MLP ASTRONOVA INC.
NWPP MAUI LAND & PINEAPPLE CO. INC.
BHC NEW PEOPLES BANKSHARES INC.
DLHC BAUSCH HEALTH COMPANIES INC.
MNR DALEIGH HOLDINGS CORP
SUNS MACH NATURAL RESOURCES LP
HYMC SUNRISE REALTY TRUST
HYCROFT MINING HOLDING CORPORATION
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule ...
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) DUBLIN, June 16, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to two new employees to purchase 9,600 ordinary shares under Avadel’s 2021 Inducement Plan. In addition, effective as of May 13, 2025, the Compensation Committee of Avadel’s Board of Directors approved a grant of non-statutory options to Susa...
- Jonathan Moreland
KMPR KEMPER CORPORATION
IPAR INTER PARFUMS INC.
GLP GLOBAL PARTNERS LP
VSH VISHAY INTERTECHNOLOGY INC.
KYN KAYNE ANDERSON MLP INVESTMENT CO.
BMBL BUMBLE
AIRS AIRSCULPT TECHNOLOGIES INC
TYRA TYRA BIOSCIENCES INC
ERNA ETERNA THERAPEUTICS INC.
SDHC SMITH DOUGLAS HOMES CORP
TG Therapeutics to Participate in the Goldman Sachs 46th Annual Global...
TG Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference Fireside chat scheduled for Tuesday, June 10, 2025, at 10:40am ET. NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the Goldman Sachs 46th Annual Global Healthcare Conference, being held in Miami, FL on June 9-11, 2025. The fireside chat is scheduled to take place on Tuesday, June 10, 2025, at 10:40am ET. A live webcast of the fireside chat will be avail...
Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for L...
Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia DUBLIN, June 05, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that LUMRYZTM has been granted Orphan Drug Designation (ODD) from the U.S. Food & Drug Administration (FDA) for the treatment of Idiopathic Hypersomnia (IH). Specifically, ODD was granted based on the plausible hypothesis that LUMRYZ ma...
TG Therapeutics to Participate in the Jefferies Global Healthcare Conf...
TG Therapeutics to Participate in the Jefferies Global Healthcare Conference Fireside chat scheduled for Wednesday, June 4, 2025, at 12:50pm ET NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the Jefferies Global Healthcare Conference, being held at the Marriott Marquis, in New York City on June 3-5, 2025. The fireside chat is scheduled to take place on Wednesday, June 4, 2025, at 12:50 PM ET. A live webcast of the fireside chat will be availab...
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple S...
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting NEW YORK, May 30, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentations of data highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2025 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting. Links to each presentation are included below. “We were pleased to present three encore presentations yesterday during the CM...
Avadel Pharmaceuticals to Present New Data on LUMRYZ™ (sodium oxybate)...
Avadel Pharmaceuticals to Present New Data on LUMRYZ™ (sodium oxybate) For Extended-Release Oral Suspension at SLEEP 2025 – 14 abstracts accepted, including four oral presentations – – Interim analysis of real-world REFRESH study demonstrated clinically significant efficacy and improvement of EDS for patients who switched from twice-nightly oxybate to once-at-bedtime LUMRYZ – – Data reflecting the therapeutic results of LUMRYZ treatment in people with narcolepsy across clinical as well as real-world settings will be presented – DUBLIN, Ireland, May 29, 2025 (GLOBE NE...
Avadel Pharmaceuticals to Present at the Jefferies Global Healthcare C...
Avadel Pharmaceuticals to Present at the Jefferies Global Healthcare Conference DUBLIN, Ireland, May 29, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5 at 10:30 a.m. ET. A live webcast of the fireside chat, as well as an archived recording, will be available on Avadel’s Investor Relations website, , for 90 days following the conference. Ab...
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® ...
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients with relapsing forms of multiple sclerosis (RMS), at the 2025 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting, being held May 28-31, 2025 in Phoenix, Arizona. Abstracts are now available online and can be accessed on the CMSC ...
Saul Centers Inc: 1 director
A director at Saul Centers Inc bought 10,000 shares at 33.489USD and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...
- Jonathan Moreland
OEC ORION ENGINEERED CARBONS SA
LTRX LANTRONIX INC.
LGND LIGAND PHARMACEUTICALS INCORPORATED
NEWT NEWTEK BUSINESS SERVICES INC.
HTLD HEARTLAND EXPRESS INC.
UEIC UNIVERSAL ELECTRONICS INC.
VSH VISHAY INTERTECHNOLOGY INC.
FLL FULL HOUSE RESORTS INC.
FLWS
NINE 1-800-FLOWERS.COM CL A
CNX NINE ENERGY SERVICE INC
A2H9KJ CONSOL ENERGY INC.
TCPC NEO PERFORMANCE MATERIAL
MIDD BLACKROCK TCP CAPITAL CORP.
ENR THE MIDDLEBY CORPORATION
PHAT EDGEWELL PERSONAL CARE COMPANY
DLHC PHATHOM PHARMACEUTICALS
MINM DALEIGH HOLDINGS CORP
STGW MINIM
NVCT INC.
PFHC STAGWELL INC
RXO_w NUVECTIS PHARMA INC
FTK PROFRAC HLDG CORP
NCDL RXO INC
DMA FLOTEK INDUSTRIES INC.
GF NUVEEN CHURCHILL DIRECT LENDING CORP
IAE DESTRA MULTI ALTERNATIVE FUND
THRM THE NEW GERMANY FUND
AESI INC.
ING ASIA PACIFIC HIGH DIVIDEND EQUITY INCOME FUND
SOLTA MEDICAL, INC
ATLAS ENERGY SOLUTIONS INC.
Full House Resorts Announces Appointment of Joshua Le Duff as Senior ...
Full House Resorts Announces Appointment of Joshua Le Duff as Senior Vice President and Chief Marketing Officer LAS VEGAS, May 13, 2025 (GLOBE NEWSWIRE) -- Full House Resorts, Inc. (Nasdaq: FLL) (the “Company”) today announced that it has named Joshua Le Duff as its Senior Vice President and Chief Marketing Officer, subject to customary gaming approvals. Mr. Le Duff has extensive marketing experience in the casino industry, including in regional casino gaming markets. Most recently, he served as Vice President of Marketing at Pala Casino Spa Golf Resort, a AAA Four Diamond property and ...
Avadel Pharmaceuticals Expands Leadership Team with Appointment of Sus...
Avadel Pharmaceuticals Expands Leadership Team with Appointment of Susan Rodriguez as Chief Operating Officer DUBLIN, May 13, 2025 (GLOBE NEWSWIRE) -- DUBLIN, May 13, 2025 – Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the appointment of Susan Rodriguez as Chief Operating Officer. In this newly created role, Ms. Rodriguez will lead all aspects of the Company's commercial strategy, structure, organization, and related operations, including supply chain. “Susan is an accomplished biopharma execu...
Avadel Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Bi...
Avadel Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference DUBLIN, May 13, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on Tuesday, May 20 at 12:00 p.m. ET. A live webcast of the fireside chat, as well as an archived recording, will be available on Avadel’s Investor Relations website, , for 90 days follo...
- Jonathan Moreland
RGR STURM RUGER & COMPANY INC.
PEB PEBBLEBROOK HOTEL TRUST
PCAR PACCAR INC
NG. NOVAGOLD RESOURCES INC.
NBTB NBT BANCORP INC.
MTX MINERALS TECHNOLOGIES INC.
MTDR MATADOR RESOURCES COMPANY
MMLP MARTIN MIDSTREAM PARTNERS L.P.
IFF INTERNATIONAL FLAVORS & FRAGRANCES INC.
HUN HUNTSMAN CORPORATION
HL HECLA MINING COMPANY
CHDN CHURCHILL DOWNS INCORPORATED
CFFN CAPITOL FEDERAL FINANCIAL INC.
CBRL CRACKER BARREL OLD COUNTRY STORE INC.
BIIB BIOGEN INC.
APLE APPLE HOSPITALITY REIT INC
OFIX ORTHOFIX INTERNATIONAL N.V.
CAT CATERPILLAR INC.
ARCB ARCBEST CORPORATION
HTLD HEARTLAND EXPRESS INC.
USAC USA COMPRESSION PARTNERS LP
NHC NATIONAL HEALTHCARE CORP.
JELD JELD-WEN HOLDING INC.
FCNCA FIRST CITIZENS BANCSHARES INC. CLASS A
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
OCSL OAKTREE SPECIALTY LENDING CORPORATION
SNBR SLEEP NUMBER CORPORATION
RCII RENT-A-CENTER INC
A2H9KJ NEO PERFORMANCE MATERIAL
KKR KKR & CO. INC.
REZI RESIDEO TECHNOLOGIES
TROX INC.
UTGN TRONOX HOLDINGS PLC
CCO UTG
AVTR CLEAR CHANNEL OUTDOOR HOLDINGS INC
GCI AVANTOR
DCTH INC.
ONEW GANNETT CO. INC.
DLHC DELCATH SYSTEMS
UTZ ONEWATER MARINE
OGN DALEIGH HOLDINGS CORP
NVCT UTZ BRANDS INC (A)
PRAA ORGANON & CO
VSTS_w NUVECTIS PHARMA INC
BNL PORTFOLIO RECOVERY ASSOCIATES
DMA INC.
SUNS VESTIS CORPORATION
GF BROADSTONE NET LEASE INC
FG DESTRA MULTI ALTERNATIVE FUND
EU SUNRISE REALTY TRUST
ECF THE NEW GERMANY FUND
HCWB INC.
F AND G ANNUITIES AND LIFE
INC.
WISDOMTREE EURO DEBT FUND
ELLSWORTH FUND LTD
HCW BIOLOGICS INC
FULL HOUSE RESORTS ANNOUNCES FIRST QUARTER RESULTS
FULL HOUSE RESORTS ANNOUNCES FIRST QUARTER RESULTS - Revenues Increased 7.3% in the First Quarter of 2025 - American Place Casino Achieved a New Property Record in March 2025, Reaching $10.9 Million of Monthly Gaming Revenue - Revenues from Our Colorado Operations Increased 33.9% in the First Quarter of 2025 - Silver Slipper Benefited from New Leadership and Operational Improvements LAS VEGAS, May 08, 2025 (GLOBE NEWSWIRE) -- Full House Resorts, Inc. (Nasdaq: FLL) today announced results for the first quarter ended March 31, 2025. On a consolidated basis, revenues in the first quar...
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule ...
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) DUBLIN, May 08, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to nine (9) new employees to purchase 51,700 ordinary shares under Avadel’s 2021 Inducement Plan. The awards were granted as an inducement material to the employee’s acceptance of employment with Avadel in accordance with Nasdaq Listing Rule 5...
- Jonathan Moreland
PEB PEBBLEBROOK HOTEL TRUST
PCAR PACCAR INC
NEO NEOGENOMICS INC.
NBTB NBT BANCORP INC.
MMLP MARTIN MIDSTREAM PARTNERS L.P.
HUN HUNTSMAN CORPORATION
HL HECLA MINING COMPANY
CHDN CHURCHILL DOWNS INCORPORATED
HTLD HEARTLAND EXPRESS INC.
NHC NATIONAL HEALTHCARE CORP.
OCSL OAKTREE SPECIALTY LENDING CORPORATION
RCII RENT-A-CENTER INC
GCI GANNETT CO. INC.
OGN ORGANON & CO
EU WISDOMTREE EURO DEBT FUND
Avadel Pharmaceuticals Reports First Quarter 2025 Financial Results an...
Avadel Pharmaceuticals Reports First Quarter 2025 Financial Results and Raises Guidance -- Generated $52.5 million in net revenue from sales of LUMRYZ™, a 93% increase over the first quarter of 2024 -- -- 2,800 patients on LUMRYZ as of March 31, 2025, a net increase of 300 patients since December 31, 2024 and a 100% year over year increase over the first quarter of 2024 -- -- Raises 2025 guidance; expects to generate $255 - $265 million in net product revenue and cash flow of $30 - $40 million, driven by 3,400 - 3,600 patients on LUMRYZ by year end -- -- Federal Circuit ruled in Avadel’s...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.